The double blind, placebo controlled trial will enroll 40 patients with prodromal or mild Alzheimer’s disease to measure physical changes in the brains of patients treated with PBT2 for 12 months and evaluate the effects of PBT2 on patients’ cognition reported in the earlier trial.

The 12-month trial is based on the success of an earlier Phase IIa clinical trial of PBT2 that showed an improvement in cognition.

Prana executive chairman Geoffrey Kempler said the earlier 12-week trial reported an improvement in cognition and change in Abeta levels in spinal fluid.

”We believe that in this 12 month trial PBT2 will establish its credentials as a safe and effective treatment for Alzheimer’s Disease,” Kempler added.